Atomo Diagnostics Ltd (at1) Logo

Atomo Diagnostics Ltd (AT1)

___:___ · AUD

AT1 Chart

AT1's Principal Activity is the development and sale of medical devices.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -55.90%
vs ASX 200 (1yr) -69.38%


Market Capitalisation
ASX Rank 1,086 of 2,295
Sector Rank 90 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies GTG / EX1 / AGH
EPS -$0.005
DPS $0.00
NTA per share $0.05

Broker Consensus

AT1 is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Company Overview

Atomo Diagnostics Limited (AT1) is a medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, viral vs bacterial differentiation and female health.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Leichhardt NSW 2040
Registry Link Market Services
Auditor BDO Audit Pty Ltd
Date Listed 16 Apr 2020

Upcoming Calendar (Forecasted)

No calendar entries available.

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Constance (Connie) Bernadette Carnabuci Non-Executive Director Feb 2020 Director Bio icon

Ms Constance (Connie) Bernadette Carnabuci

Non-Executive Director

Ms Carnabuci has over 30 years of experience advising intellectual property and technology businesses in Australia and across Asia on commercial, corporate and regulatory matters. Ms Carnabuci holds an executive role as the General Counsel of the Australian Broadcasting Corporation. She is a professional Non-Executive Director and currently serves on the Board and the Remuneration Committee of OFX. Ms Carnabuci is a former partner of Mallesons Stephen Jacques and Freshfields Bruckhaus Deringer. She is a member of the Business Advisory Council of the UNSW Business School. She serves as the Vice President of the Cranbrook School Parents Association. She was the Chair of the NFP, Kids Giving Back, from 2015 to 2018.

Dr Curt Harold LaBelle Non-Executive Director Oct 2016 Director Bio icon

Dr Curt Harold LaBelle

Non-Executive Director

Dr LaBelle has been involved in the healthcare industry for 20 years, both operationally and as an investor. Dr LaBelle is President at the Global Health Investment Fund (GHIF). He also serves as a director on the boards of Alydia Health, Evenovia and Atticus Medical. Prior to joining GHIF, Dr LaBelle was Managing Director at Tullis Health Investors and Vice President at Investor Growth Capital. He is a former chairman of Impulse Monitoring (acquired by Nuvasive), Exagen Inc. (NASDAQ:XGN) and a former director of Sirion Therapeutics (products acquired by Alcon and Bausch), SafeOp Surgical (acquired by AlphaTec) and KAI Pharmaceuticals (acquired by Amgen). Dr LaBelle is also the member of Risk committee.

Mr John Perry Keith Non-Executive Chairman,Non-Executive Director Dec 2011 Director Bio icon

Mr John Perry Keith

Non-Executive Chairman,Non-Executive Director

Mr Keith is a Managing Director of BNP Paribas, establishing and leading its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign and institutional clients across all areas of investment and institutional banking. He has also served on the boards of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation. He is also the member of Risk committee.

Mr John Michael Kelly Founder,Chief Executive Officer,Managing Director Apr 2010 Director Bio icon

Mr John Michael Kelly

Founder,Chief Executive Officer,Managing Director

Mr Kelly was into developing and commercialising medical devices for more than 20 years to enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to co-founding Atomo in 2010, Mr Kelly acted as the Chief Operating Officer (COO) of Unilife Corporation, which was previously an ASX-listed company (ASX:UNS) and subsequent to his departure, a Nasdaq listed company (NASDAQ:UNIS). At Unilife Corporation, he led the global operations team from 2005 to 2008, developing 'Unifill'. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of Mirage Swift and Activa mask systems.

Dr Paul Alexander Kasian Non-Executive Director N/A Director Bio icon

Dr Paul Alexander Kasian

Non-Executive Director

Dr Kasian is an experienced executive director in both domestic and international companies in senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. Previously he served as a Non-Executive Director, then Chairman and CEO of Genetic Technologies Limited (appointed 12 December 2013 and resigned 23 September 2019). Dr Kasian is the Chair of the Risk Committee.

Ms Gillian Maria Nairn Company Secretary N/A
Fabio Baglioni Chief Commercial Officer N/A
William Souter Chief Financial Officer N/A
Mark Smith Chief Operating Officer N/A

Director Transactions

AT1 directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
09/04/21 Curt LaBelle Buy +960,000 $0.156 $150,000 Exercise of options
09/04/21 Curt LaBelle Exercise 960,000 $0.156 $150,000 Exercise of options
09/04/21 Curt LaBelle Buy +240,000 $0.156 $37,500 Exercise of options
09/04/21 Curt LaBelle Exercise 240,000 $0.156 $37,500 Exercise of options

Director Interests

The current holdings of AT1 directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Curt LaBelle 09/04/2021 240,000 64,811,280 2,400,000 N/A
John Kelly 30/06/2020 7,370,248 66,160,000 2,000,000 N/A
John Keith 30/06/2020 3,261,056 N/A 3,600,000 N/A
Constance (Connie) Carnabuci 30/06/2020 N/A 75,000 N/A N/A
Paul Kasian 30/06/2020 N/A 100,000 N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Sep 25, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Dalraida Holdings Pty Limited 66,160,000 11.79%
Global Health Investment Fund I Llc 63,851,280 11.38%
Walker Group Holdings Pty Ltd 46,660,718 8.32%
National Nominees Limited 32,478,361 5.79%
J P Morgan Nominees Australia Pty Limited 18,556,834 3.31%
HSBC Custody Nominees (Australia) Limited 17,624,130 3.14%
Blueflag Holdings Pty Ltd 13,760,000 2.45%
Grand Challenges Canada 11,390,824 2.03%
Liverbird Pty Ltd 9,731,653 1.73%
Sokolov Pty Ltd 9,202,181 1.64%
I D E Pty Ltd <Atf Ide Trust> 9,032,248 1.61%
Mark Andrew Smith 7,790,224 1.39%
John Michael Kelly 7,370,248 1.31%
Leo James Lynch & Judith Anne Beswick 7,321,121 1.30%
Bnp Paribas Noms Pty Ltd 6,972,741 1.24%
Hsbc Custody Nominees (Australia) Limited A/C 2 6,528,750 1.16%
Mr Ian Fredrick Johnson 6,079,560 1.08%
Bosana Nominees Pty Ltd 5,881,496 1.05%
Ruth Karen Devney 5,626,408 1.00%
Nicola Jayne Rigby 4,846,220 0.86%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 403 4,087 1,488 2,501 314 8,793

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
John Kelly 25/09/2020 73,530,248 13.11
Ellerston Capital Limited 25/09/2020 34,375,000 6.13
Global Health Investment Fund I LLC 25/09/2020 63,851,280 11.38
Perennial Value Management Limited 29/06/2021 42,962,957 7.56
Walker Group Holdings Pty Limited 19/10/2020 37,660,718 6.70

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
29-06-21 Perennial Value Management Limited 7,334,006 6.35 7.56

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
19-10-20 Walker Group Holdings Pty Limited 9,000,000 8.32 6.70
25-08-20 Perennial Value Management Limited 6,133,553 7.44 6.35

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.34 30 June
Page Icon
AT1 Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.